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Background: Although several studies showed that decreased soluble receptor for advanced glycation end
products (sRAGE) is associated with metabolic syndrome (MetS), inflammation level has not been considered, even
though ligand–RAGE interaction induces inflammation. The objective of the study was to determine the association
between sRAGE and MetS among Japanese adult in a cross-sectional survey, taking the level of low grade
inflammation into consideration.
Methods: Serum soluble RAGE (sRAGE) were measured in 712 men and 176 women aged 30–83 years with serum
C-reactive protein (hsCRP) concentration below 3 mg/L. MetS was defined using the criteria of the American Heart
Association Scientific Statements of 2009.
Results: After multivariable adjustment, among men, higher sRAGE levels were associated with lower odds of MetS
as well as central obesity and elevated blood pressure. Comparing the extreme tertiles of sRAGE, odds ratios
(95% confidence interval) were 0.58 (0.36–0.95; P for trend = 0.001) for MetS; 0.41 (0.25–0.52; P for trend < 0.001) for
central obesity; and 0.45 (0.29–0.70; P for trend < 0.001) for elevated blood pressure. Moreover, participants were
categorized according to their median hsCRP and sRAGE values. Men in the higher hsCRP/higher sRAGE category
had a 40% lower odds ratio for MetS than those in the higher hsCRP/lower sRAGE category (P = 0.031). Among
women, there was no association between sRAGE levels and the prevalence of MetS.
Conclusions: Higher circulating RAGE concentrations were associated with lower prevalence of MetS and its
components among Japanese men.
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The receptor for advanced glycation end products (RAGE)
is a cell surface molecule belonging to the immunoglobulin
superfamily that binds many ligands including advanced
glycation end products (AGEs) [1]. Circulating forms of
RAGE, arising from receptor ectodomain shedding [soluble* Correspondence: nagatomi@med.tohoku.ac.jp
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reproduction in any medium, provided the orRAGE (sRAGE)] and secretion of its splice variant [en-
dogenous secretory RAGE (esRAGE)], may competitively
inhibit binding of the ligand to membrane-bound RAGE
by acting as an endogenous decoy [2]. Indeed, in animal
models, recombinant sRAGE administration suppressed the
development of atherosclerosis and stabilized established
atherosclerosis [3,4]. Thus, circulating RAGE (sRAGE and
esRAGE) levels may inversely reflect ligand−RAGE inter-
action evoked pathogenesis.
Several studies have reported that decreased circulating
RAGE concentrations are associated with metabolic syn-
drome (MetS) risk factors [5-9]. Moreover, participantsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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concentration than those without MetS [7], and plasma
sRAGE levels decreased with increasing number of MetS
risk factors [10]. Proinflammatory state [e.g., high concen-
tration of C-reactive protein (CRP)] is considered to have a
significant impact on the pathogenesis of MetS and its
components [11]. Under low grade chronic inflammation
circumstances, higher sRAGE level may attenuate the de-
teriorating effect of inflammation on MetS and its compo-
nents. However, such association has not been investigated.
Thus, the purpose of this study was to examine the asso-
ciation between circulating RAGE (sRAGE and esRAGE)
concentrations and the prevalence of MetS in Japanese
adult in a population-based cross-sectional study, with




The study participants comprised adult employees enrolled
in a prospective study of risk factors for lifestyle-related ill-
nesses or health status at the Sendai Oroshisho Center in
Sendai, Japan. The participants received annual health ex-
aminations in 2009. This study was conducted during the
first week (from Monday to Friday) of August. The details
of this study have been described previously [12].
The sample selection process is described in Figure 1. In
2009, 1 263 participants had undergone health examina-
tions for lifestyle-related illnesses. Of these, 1 215 partici-
pated in our survey and provided informed consent for
data analysis (response rate, 96.2%). The following partici-
pants were excluded: those for whom sRAGE or esRAGEFigure 1 Flow chart of the sample selection process. sRAGE, soluble re
secretory RAGE. hsCRP, high sensitivity C-reactive protein.measurements were unavailable (n = 5); those with a his-
tory of cardiovascular disease (n = 8); those whose serum
CRP concentration was ≥ 3.0 mg/L (n = 64), because
people with above 3 mg/L of CRP are considered as being
in high risk for cardiovascular disease [13]; and those for
whom complete data was not available (n = 250). Thus,
712 men and 176 women were included in the present
study. The protocol of this study was approved by the
Institutional Review Board of the Tohoku University Gradu-
ate School of Medicine.
Assessment of MetS
Fasting blood samples were drawn from the antecubital
vein with minimal tourniquet use, with the participants in a
seated position. Samples were collected in siliconized vac-
uum glass tubes containing sodium fluoride for fasting
blood glucose (FBG) analysis, and with no additives for lipid
analysis. The FBG concentration was measured enzymati-
cally (Eerotec Co., Ltd., Tokyo, Japan). The concentrations
of triglycerides (TG), low-density lipoprotein cholesterol
(LDL-C), and high-density lipoprotein cholesterol (HDL-C)
were also measured by enzymatic methods using appropri-
ate kits (Sekisui Medical Co., Ltd., Tokyo, Japan). Blood
pressure (BP) was measured twice from the upper left arm
by means of an automatic device (Yamasu 605P; Kenzme-
dico, Saitama, Japan) after the participants had rested for
5 min in a sitting position and the mean of the 2 measure-
ments was taken as the BP value. Waist circumference
(WC) was measured at the umbilical level with the partici-
pants in a standing position and breathing normally. The
criteria of the American Heart Association Scientific State-
ments of 2009 were used to define MetS [14]. Theceptor for advanced glycation end products. esRAGE, endogenous
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sented ≥3 of the following risk factors: (1) central obesity
(≥ 90 cm for men and ≥ 80 cm for women) (2) elevated
TG (≥150 mg/dL); (3) reduced HDL-C (< 40 mg/dL for
men and < 50 mg/dL for women); (4) elevated BP [systolic
BP (SBP) ≥130 mm Hg or diastolic BP (DBP) ≥85 mm
Hg]); and (5) elevated FBG (≥100 mg/dL). Those partici-
pants who were receiving drug treatment for a given risk
factor were considered as having that risk factor.
Measurements of sRAGE and esRAGE
Serum sRAGE and esRAGE were measured using a com-
mercially available Quantikine ELISA kit (R&D System,
Inc., Minneapolis, MN) and the ELISA kit from B-Bridge
International (Sunnyvale, CA), respectively. The intra- and
interassay coefficients of variation were 2.8% and 6.4%, re-
spectively, for sRAGE and 6.8% and 6.0%, respectively, for
esRAGE. Although our hypothesis was that higher serum
sRAGE and esRAGE levels were associated with lower
prevalence of MetS, previous studies reported conflicting
findings for the role of circulating soluble for of RAGE.
Thus, because we postulated the possibility that too high
or too low serum sRAGE and esRAGE might have an
unfavorable influence on the prevalence of MetS and its
components resulting in an U or J curve relationship,
serum sRAGE and esRAGE concentrations were divided
into low, middle, and high tertiles in this study.
Assessment of other variables
High sensitivity CRP (hsCRP) concentration was deter-
mined using N-latex CRP-2 (Siemens Healthcare Japan,
Tokyo, Japan). The measurement limit of hsCRP was
0.02 mg/L, and an hsCRP value less than the measurement
limit was considered to be 0.01 mg/L. Estimated glomerular
filtration rate (eGFR) was calculated using the following
equation established by the Japanese Society of Nephrology
for Japanese subjects: eGFR (mL/min/1.73 m2) = 194 ×
[serum creatinine (mg/dL)] − 1.094 × (age) − 0.287 [15].
Anthropometric parameters (height and body weight)
were recorded using a standard protocol. Body mass
index (BMI) was calculated as weight (kg) divided by
height squared (m2).
Age, educational level (<college or ≥ college), occupation
(desk-based or not), marital status (married or unmarried),
smoking status (never, former, or current) and sleep dur-
ation (6–8 h or <6 and >8 h) were obtained through a
self-reported questionnaire survey. Daily physical activity
(PA) levels were estimated using the International Physical
Activity Questionnaire (Japanese version) [16] and divided
into three categories [<1.0, 1–22.9, or ≥23.0 metabolic
equivalent of tasks (METs) × hours/week] [17]. Total en-
ergy intake and alcohol drinking were estimated using a
brief self-administered dietary history questionnaire [18].
Alcohol drinking status was categorized into 4 groups(never, ≤3 day(s)/week, 4–6 days/week, or every day). De-
pressive symptoms were assessed according to the Japa-
nese version of the Self-Rating Depression Scale (SDS)
[19]. The participants were considered as depressed when
the SDS score was ≥40 [20].
Statistical analysis
All statistical analyses were performed using SPSS 17.0
for Windows (SPSS, Inc., Chicago, IL, USA).
The distributions of all continuous variables in this
study were skewed positively; therefore, we normalized
by log-transforming the data in our analyses. Spearman’s
rank correlation coefficient was calculated to examine
the relationship between sRAGE and esRAGE. To com-
pare the participants’ characteristics, we used the chi-
square test and ANOVA for categorical and continuous
variables, respectively. Descriptive data are represented
as the median (interquartile range) for non-adjusted con-
tinuous variables and as percentages for categorical vari-
ables. Multiple logistic regression analysis was used to
analyze the association of circulating sRAGE or esRAGE
concentration with MetS and its components. For analysis,
MetS and its components were used as dependent vari-
ables, and tertiles of sRAGE or esRAGE were used as inde-
pendent variables. Analysis was performed after adjustment
for potential confounding factors including age, smoking
status, drinking status, educational level, occupation, de-
pressive symptoms, PA, total energy consumption, sleeping
time, and eGFR (model 1); all parameters in model 1 plus
serum hsCRP concentration were used in model 2; all pa-
rameters in model 2 plus mutual MetS components were
included in model 3 for analysis of MetS components.
Moreover, because sex differences existed in the circulating
levels of RAGE and hsCRP, and in the prevalence of MetS,
we performed separate analyses for men and women. All P
values for linear trends were calculated using the median
values of sRAGE or esRAGE tertiles.
To examine the influence of inflammatory levels on
the association between sRAGE and MetS, participants
were categorized into higher hsCRP/lower sRAGE, higher
hsCRP/higher sRAGE, lower hsCRP/lower sRAGE, or
lower hsCRP/higher sRAGE categories according to the
median values. Using these categories as independent vari-
ables, multiple logistic regression analysis was performed,
adjusted for the model 1 and model 4 including all param-
eters in model 3 except for serum hsCRP concentration.
All tests for statistical significance were two-sided and P <
0.05 was defined as statistically significant.
Results
Of the 712 men, 179 (25.1%) had ≥3 MetS components.
The median (interquartile range) values were 1259.0
(946.4–1609.1) pg/mL for serum sRAGE, 319.0 (235.7–
432.2) pg/mL for serum esRAGE, and 0.38 (0.22–0.77)
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MetS components. The median (interquartile range)
values were 1547.9 (1139.6–1922.0) pg/mL for serum
sRAGE, 358.1 (259.3–461.5) pg/mL for serum esRAGE,
and 0.23 (0.12–0.46) mg/L for hsCRP. The concentration
of serum sRAGE was strongly correlated with the con-
centration of serum esRAGE (Figure 2).
The characteristics according to the tertiles of serum
sRAGE in men are presented in Table 1. Serum sRAGE
concentration was negatively associated with age, BMI,
WC, SBP, DBP, hsCRP (P for trend < 0.001), and TG (P for
trend = 0.036). Moreover, higher tertiles of serum sRAGE
had a lower percentage of participants with ≥23 METs ×
hours/week (P for trend = 0.011) and those who drank
7 days/week (P for trend < 0.001), and they also had a
higher percentage of current smokers (P for trend =
0.020). No other significant associations were observed be-
tween the groups. Among women, serum sRAGE concen-
tration was negatively associated with BMI, WC, SBP, and
hsCRP (Additional file 1: Table S1).
The prevalence of MetS was 30.7% in the lowest tertile of
serum sRAGE, 27.4% in the middle tertile, and 17.3% in
highest tertile (P for trend = 0.001, Table 1) among men.
Moreover, higher serum sRAGE concentration was nega-
tively associated with the number of MetS components
(P for trend < 0.001), and negatively associated with the
prevalence of central obesity and elevated BP (P for trend <
0.001). Similar results were obtained for women (Additional
file 1: Table S1).
Table 2 shows the relationship of tertiles of serum
sRAGE with the prevalence of MetS and its components
after adjustment for potential confounders in men. The
adjusted odds ratio (95% confidence interval) for MetS in
the middle and highest tertiles of serum sRAGE were 0.89
(0.59–1.35) and 0.45 (0.28–0.71) (P for trend = 0.001),
respectively. Even after adjustment for serum hsCRP
concentration, participants with higher serum sRAGE
concentration had a lower prevalence of MetS [1.04
(0.67–1.61) for middle tertile, and 0.58 (0.36–0.95)
for highest tertile, P for trend = 0.038]. Furthermore,Figure 2 Relationship between serum sRAGE and esRAGE in men (A)
products. esRAGE, endogenous secretory RAGE. rs, Spearman rank-correlatioparticipants with higher serum sRAGE concentration
had a lower prevalence of central obesity [0.86 (0.58–
1.27) for middle tertile, 0.33 (0.21–0.52) for highest ter-
tile, P for trend < 0.001], elevated BP [0.61 (0.40–0.93)
for middle tertile, 0.38 (0.25–0.57) for highest tertile,
P for trend < 0.001], and elevated TG [1.00 (0.68–1.48)
for middle tertile, and 0.62 (0.41–0.93) for highest ter-
tile, P for trend = 0.024], after adjustment for potential
confounders. With central obesity and elevated BP, even
after adjustment for serum hsCRP concentration (model
2) and mutual MetS components (model 3), the associ-
ation remained. Moreover, similar results were obtained
for the relationships of serum esRAGE concentration
with MetS and its components, except for reduced
HDL-C in model 1 [0.98 (0.58–1.65) for middle tertile,
and 0.44 (0.24–0.79) for highest tertile, P for trend =
0.006]. Among women, serum sRAGE level was associ-
ated with only elevated BP after adjustment for con-
founding factors (Additional file 1: Table S2).
We examined the interrelationship between sRAGE,
MetS, and hsCRP. Table 3 shows the adjusted odds ratio
(95% confidence intervals) for MetS in the higher hsCRP/
higher sRAGE, lower hsCRP/lower sRAGE, and lower
hsCRP/higher sRAGE categories in men. Participants in
the higher hsCRP/higher sRAGE category had a 40% lower
odds ratio for MetS than those in the higher hsCRP/lower
sRAGE category (P = 0.031). Moreover, after adjustment for
mutual MetS components (model 2), participants in the
higher hsCRP/higher sRAGE category had a 46% lower
odds ratio for central obesity (P = 0.020) and a 51% lower
odds ratio for elevated BP (P = 0.007) than those in the
higher hsCRP/lower sRAGE category. Among women,
there was no difference between higher hsCRP/higher
sRAGE and hsCRP/lower sRAGE category after adjustment
for confounders (Additional file 1: Table S3).
To examine the influence of those excluded because of
incomplete data, we examined the associations between cir-
culating sRAGE or esRAGE levels and the prevalence of
MetS including those who had incomplete data by comple-
menting the incomplete data. For example, the educationaland women (B). sRAGE, soluble receptor for advanced glycation end
n coefficient.
Table 1 Characteristics of the participants according to the tertiles of serum sRAGE in men (n = 712)a
Tertiles of serum sRAGE
Median, interquartile range (pg/mL) Low (n = 238) Middle (n =237) High (n =237) P for trendb
(847.6, 710.0–950.0) (1259.1, 1152.8–1377.2) (1835.0, 1608.9–2107.8)
Age (years) 51.0 (41.0–57.0) 46.0 (38.0–56.0) 44.0 (38.0–54.0) <0.001
BMI (kg/m2) 24.5 (22.3–26.1) 23.7 (21.7–26.1) 22.7 (20.9–24.4) <0.001
WC (cm) 86.0 (81.0–92.0) 85.0 (79.0–92.0) 82.0 (77.0–87.0) <0.001
SBP (mmHg) 133.0 (122.0–143.0) 130.0 (118.0–140.0) 122.0 (114.0–134.0) <0.001
DBP (mmHg) 84.5 (76.8–91.3) 82.0 (76.0–90.0) 78.0 (70.0–86.0) <0.001
TG (mg/dL) 125.5 (83.0–174.3) 115.0 (78.0–180.0) 100.0 (73.0–160.0) 0.036
LDL-C (mg/dL) 118.5 (101.8–146.0) 120.0 (101.5–139.5) 118.0 (100.0–137.0) 0.28
HDL-C (mg/dL) 52.0 (43.0–60.3) 51.0 (43.5–61.0) 51.0 (43.0–60.0) 0.34
FBG (mg/dL) 95.0 (90.0–102.3) 94.0 (88.5–103.0) 93.0 (88.0–100.0) 0.07
eGFR (ml/min/1.73 m2) 81.3 (73.7–90.4) 81.8 (73.6–90.6) 80.8 (72.4–89.1) 0.16
hsCRP (mg/L) 0.46 (0.27–0.93) 0.40 (0.21–0.78) 0.33 (0.19–0.58) <0.001
esRAGE (pg/mL) 208.1 (170.3–260.9) 320.4 (278.3–374.6) 480.9 (411.9–573.9) <0.001
Total energy intake (kcal/day) 1882.0 (1553.8–2309.5) 1866.6 (1523.5–2315.3) 1854.6 (1450.2–2196.5) 0.063
PA
<1.0 METs · hours/week (%) 20.6 20.7 26.6 0.011
1.0–22.0 METs · hours/week (%) 38.7 42.6 44.3
≥23.0 METs · hours/week (%) 40.7 36.7 29.1
Smoking status
Never smoker (%) 39.5 38.4 32.1 0.020
Former smoker (%) 15.5 10.1 10.5
Current smoker (%) 45.0 51.5 57.4
Drinking status
Non-drinker (%) 12.2 15.6 21.1 <0.001
≤ 3 day(s)/week (%) 29.0 35.4 35.4
4–6 days/week (%) 21.8 18.2 18.6
Every day (%) 37.0 30.8 24.9
Sleep time, ≥6 and ≤8 hours/day (%) 80.3 81.0 76.8 0.35
Education (≥college, %) 34.0 32.9 35.4 0.75
Desk work (%) 80.3 79.3 76.4 0.30
Being married (%) 83.6 78.5 79.3 0.24
Depressive symptoms (SDS ≥40, %) 33.6 28.7 32.1 0.72
Number of MetS components (%)
No 11.3 20.7 30.4 <0.001
1 component 31.1 26.2 34.2
2 components 26.9 25.7 18.1
≥3 components 30.7 27.4 17.3
Central obesity (%) 33.6 30.8 15.6 <0.001
Elevated BP (%) 71.0 57.4 44.3 <0.001
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Table 1 Characteristics of the participants according to the tertiles of serum sRAGE in men (n = 712)a (Continued)
Elevated FBG (%) 32.8 32.9 25.3 0.078
Elevated TG (%) 35.3 35.4 27.0 0.054
Reduced HDL-C (%) 14.7 13.5 13.9 0.81
aData are medians (interquartile range) or proportions. sRAGE, soluble receptor of advanced glycation end-products; BMI, body mass index; WC, Waist circumference;
SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; FBG,
fasting blood glucose; eGFR, estimated glomerular filtration rate; hsCRP, high sensitivity C-reactive protein; esRAGE, endogenous secretory RAGE; PA, physical activity;
SDS, Self-rating Depression Scale; MetS, metabolic syndrome.
bAnalysis of variance or χ2 test.
Table 2 Relationship of the tertile of serum sRAGE with the prevalence of MetS in men (n = 712)a
Tertiles of serum sRAGE
Median, interquartile range (pg/mL) Low (n = 238) Middle (n =237) High (n =237) P for trendb
(847.6, 710.0–950.0) (1259.1, 1152.8–1377.2) (1835.0, 1608.9–2107.8)
MetS
Crude 1.00 0.85 (0.57–1.27) 0.47 (0.31–0.73) <0.001
Model 1c 1.00 0.89 (0.59–1.35) 0.45 (0.28–0.71) 0.001
Model 2d 1.00 1.04 (0.67–1.61) 0.58 (0.36–0.95) 0.038
Central obesity
Crude 1.00 0.88 (0.60–1.29) 0.37 (0.24–0.57) <0.001
Model 1c 1.00 0.86 (0.58–1.27) 0.33 (0.21–0.52) <0.001
Model 2d 1.00 0.96 (0.64–1.45) 0.41 (0.25–0.66) <0.001
Model 3e 1.00 0.99 (0.65–1.52) 0.46 (0.28–0.75) 0.003
Elevated BP
Crude 1.00 0.55 (0.38–0.80) 0.33 (0.22–0.48) <0.001
Model 1c 1.00 0.61 (0.40–0.93) 0.38 (0.25–0.57) <0.001
Model 2d 1.00 0.66 (0.43–1.02) 0.45 (0.29–0.70) <0.001
Model 3e 1.00 0.65 (0.42–1.01) 0.49 (0.31–0.77) 0.002
Elevated FBG
Crude 1.00 1.01 (0.69–1.48) 0.70 (0.47–1.04) 0.078
Model 1c 1.00 1.17 (0.78–1.75) 0.89 (0.58–1.37) 0.64
Model 2d 1.00 1.21 (0.81–1.84) 0.97 (0.63–1.51) 0.95
Model 3e 1.00 1.29 (0.85–1.96) 1.20 (0.76–1.89) 0.40
Elevated TG
Crude 1.00 1.01 (0.69–1.47) 0.68 (0.46–1.03) 0.054
Model 1c 1.00 1.00 (0.68–1.48) 0.62 (0.41–0.93) 0.024
Model 2d 1.00 1.11 (0.74–1.65) 0.75 (0.49–1.65) 0.19
Model 3e 1.00 1.17 (0.77–1.77) 0.85 (0.54–1.33) 0.50
Reduced HDL-C
Crude 1.00 0.91 (0.54–1.52) 0.94 (0.56–1.57) 0.81
Model 1c 1.00 0.77 (0.44–1.33) 0.63 (0.36–1.11) 0.11
Model 2d 1.00 0.88 (0.45–1.56) 0.87 (0.46–1.56) 0.65
Model 3e 1.00 0.85 (0.47–1.53) 0.90 (0.48–1.68) 0.74
aData are odds (95% confidence interval). sRAGE, soluble receptor of advanced glycation end-products; MetS, metabolic syndrome.
bMultiple logistic regression analysis.
cAdjusted for age (continuous variable), smoking status (never, former, or current), drinking status (never, ≤ 3 day(s)/week, 4–6 days/week, or every day),
educational level (≥college or not), occupation (desk work or non-desk work), depressive symptoms (Self-Rating Depression Scale ≥40 or not), physical activity
(<1.0 METs · hour/week, 1.0–22.9 METs · hour/week, or ≥23.0 METs · hour/week), total energy intake (continuous variable), sleep time (≥6 and ≤8 hours/day or not),
and eGFR (continuous variable).
dAdditionally adjusted for serum high sensitivity C-reactive protein concentration (continuous variable).
eAdditionally adjusted for mutual metabolic syndrome components.
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Table 3 Odds ratios of MetS risk factors by hsCRP and sRAGE categories in men (n = 712)a
Crude Model 1c
MetS Odds ratio (95% CI) Pb Odds ratio (95% CI) Pb
Higher hsCRP/lower sRAGE (n = 192) 1 1
Higher hCRP/higher sRAGE (n = 161) 0.65 (0.42–1.01) 0.057 0.60 (0.37–0.95) 0.031
Lower hsCRP/lower sRAGE (n = 164) 0.26 (0.16–0.43) <0.001 0.26 (0.15–0.43) <0.001
Lower hsCRP/higher sRAGE (n = 195) 0.16 (0.09–0.27) <0.001 0.16 (0.09–0.28) <0.001
Crude Model 1c Model 4d
Central obesity Odds ratio (95% CI) Pb Odds ratio (95% CI) Pb Odds ratio (95% CI) Pb
Higher hsCRP/lower sRAGE (n = 192) 1 1 1
Higher hCRP/higher sRAGE (n = 161) 0.56 (0.36–0.87) 0.010 0.50 (0.31–0.79) 0.003 0.56 (0.35–0.92) 0.020
Lower hsCRP/lower sRAGE (n = 164) 0.38 (0.24–0.61) <0.001 0.38 (0.23–0.61) <0.001 0.48 (0.30–0.80) 0.004
Lower hsCRP/higher sRAGE (n = 195) 0.17 (0.10–0.28) <0.001 0.15 (0.09–0.26) <0.001 0.21 (0.12–0.37) <0.001
Crude Model 1c Model 4d
Elevated BP Odds ratio (95% CI) Pb Odds ratio (95% CI) Pb Odds ratio (95% CI) Pb
Higher hsCRP/lower sRAGE (n = 192) 1 1 1
Higher hCRP/higher sRAGE (n = 161) 0.40 (0.26–0.63) <0.001 0.43 (0.26–0.71) 0.001 0.49 (0.30–0.83) 0.007
Lower hsCRP/lower sRAGE (n = 164) 0.47 (0.30–0.73) 0.001 0.41 (0.25–0.67) <0.001 0.54 (0.32–0.90) 0.019
Lower hsCRP/higher sRAGE (n = 195) 0.24 (0.16–0.37) <0.001 0.25 (0.15–0.40) <0.001 0.35 (0.21–0.58) <0.001
Crude Model 1c Model 4d
Elevated FBG Odds ratio (95% CI) Pb Odds ratio (95% CI) Pb Odds ratio (95% CI) Pb
Higher hsCRP/lower sRAGE (n = 192) 1 1 1
Higher hCRP/higher sRAGE (n = 161) 0.75 (0.48–1.16) 0.20 0.87 (0.54–1.39) 0.56 1.04 (0.64–1.68) 0.88
Lower hsCRP/lower sRAGE (n = 164) 0.51 (0.32–0.80) 0.004 0.50 (0.31–0.81) 0.005 0.61 (0.37–1.00) 0.050
Lower hsCRP/higher sRAGE (n = 195) 0.47 (0.30–0.73) 0.001 0.60 (0.38–0.96) 0.031 0.86 (0.52–1.42) 0.56
Crude Model 1c Model 4d
Elevated TG Odds ratio (95% CI) Pb Odds ratio (95% CI) Pb Odds ratio (95% CI) Pb
Higher hsCRP/lower sRAGE (n = 192) 1 1 1
Higher hCRP/higher sRAGE (n = 161) 0.91 (0.59–1.39) 0.66 0.86 (0.54–1.32) 0.46 1.01 (0.63–1.63) 0.96
Lower hsCRP/lower sRAGE (n = 164) 0.52 (0.34–0.82) 0.004 0.55 (0.35–0.84) 0.011 0.77 (0.47–1.25) 0.29
Lower hsCRP/higher sRAGE (n = 195) 0.34 (0.21–0.53) <0.001 0.34 (0.21–0.54) <0.001 0.53 (0.32–0.89) 0.015
Crude Model 1c Model 4d
Reduced HDL-C Odds ratio (95% CI) Pb Odds ratio (95% CI) Pb Odds ratio (95% CI) Pb
Higher hsCRP/lower sRAGE (n = 192) 1 1 1
Higher hCRP/higher sRAGE (n = 161) 1.09 (0.65–1.82) 0.76 0.78 (0.45–1.38) 0.40 0.79 (0.43–1.47) 0.46
Lower hsCRP/lower sRAGE (n = 164) 0.35 (0.18–0.68) 0.002 0.39 (0.19–0.77) 0.007 0.44 (0.21–0.93) 0.032
Lower hsCRP/higher sRAGE (n = 195) 0.34 (0.18–0.64) 0.001 0.27 (0.14–0.54) <0.001 0.37 (0.18–0.78) 0.009
aParticipants were categorized by the median values (1259.0 pg/mL for sRAGE; 0.38 mg/L for hsCRP). CI, confidential interval ; sRAGE, soluble receptor of
advanced glycation end-products; BP, blood pressure; FBG, fasting blood glucose; TG, triglyceride; HDL-C, high density lipoprotein cholesterol.
bMultiple logistic regression analysis.
cAdjusted for age (continuous variable), smoking status (never, former, or current), drinking status (never, ≤ 3 day(s)/week, 4–6 days/week, or every day),
educational level (≥college or not), occupation (desk work or non-desk work), depressive symptoms (Self-Rating Depression Scale ≥40 or not), physical activity
(<1.0 METs · hour/week, 1.0–22.9 METs · hour/week, or ≥23.0 METs · hour/week), total energy intake (continuous variable), sleep time (≥6 and ≤8 hours/day or not),
and eGFR (continuous variable).
dAdditionally adjusted for mutual metabolic syndrome components.
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value group, and physical activity was categorized into <1.0,
1–22.9, ≥23.0 METs · hours/week, or missing value group.
For continuous variables including eGFR and energy intake,
missing values were assigned to their medians. In model 2,for men, the adjusted odds ratio (95% confidence interval)
for MetS in the middle and highest tertiles of serum
sRAGE were 0.83 (0.56–1.26) and 0.46 (0.29–0.72) (P for
trend = 0.001), respectively. Among women, even inclu-
sion of participants with incomplete data, there was no
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and MetS. Moreover, for the interrelationship between
sRAGE, MetS, and hsCRP among men, participants in the
higher hsCRP/higher sRAGE category had a 40% lower
odds for MetS than those in the higher hsCRP/lower
sRAGE category (0.59 [0.38–0.92], P = 0.021).
Discussion
The present study examined the association between the
levels of circulating RAGE (sRAGE and esRAGE) and
prevalence of MetS and its component among adult with
low grade inflammatory level, through a population-
based cross-sectional study. Our results suggested that,
among men, after adjustment for serum hsCRP concen-
tration higher circulating RAGE levels were associated
with lower prevalence of MetS, central obesity, and ele-
vated BP. Moreover, participants in the higher hsCRP/
higher sRAGE category had lower odds ratio of MetS
than those in the higher hsCRP/lower sRAGE category.
Thus, higher levels of circulating RAGE were associated
with lower prevalence of MetS and its components in-
cluding central obesity and elevated BP among adult
men with low grade inflammation.
Previous studies have reported a relationship between
circulating RAGE level and MetS [7,10]. For example,
Koyama et al. reported that participants with MetS had
lower circulating esRAGE concentration than those
without it, using a univariate model among type 2 dia-
betic patients and healthy controls [7]. Recently, in
young to middle-aged medication-free non-diabetic sub-
jects, plasma sRAGE concentration was found to de-
crease as the number of MetS risk factors increased [10].
In the present study, we focused on the relationship be-
tween circulating RAGE level and the prevalence of
MetS because (i) a proinflammatory state, such as high
concentration of circulating CRP, was reported to signifi-
cantly influence the pathogenesis of MetS and its com-
ponents [11], and (ii) circulating soluble forms of RAGE
may attenuate inflammatory responses via competitive
inhibition of ligand-RAGE interaction [2]. However, our
finding showed that the significant negative association
between serum sRAGE level and the prevalence of MetS
remained after adjusting for serum hsCRP level. Therefore,
circulating sRAGE as an anti-inflammatory decoy may not
be sufficient to explain the contributions of circulating
sRAGE to the lower prevalence of MetS. In addition, in the
present study, the mean (SD) serum sRAGE concentration
was 1344.8 (563.9) pg/ml. Although the concentrations of
circulating ligands for RAGE were not measured in this
study, a previous study of Japanese adult men reported that
the concentration of circulating high mobility group box 1,
a RAGE ligand, was 1.69 (0.04) ng/ml [21]. As RAGE is
known to be a multi-ligand receptor, the potential ligand
concentration likely exceeds the sRAGE concentration.Therefore, it remains unknown whether the concentration
of circulating soluble forms of RAGE is sufficient to scav-
enge accumulating ligands [22].
One of the potential mechanisms explaining the contri-
bution of sRAGE to the decreased incidence of MetS is
polymorphisms in RAGE. Kankova et al. [23] demonstrated
that subjects bearing the 1704 T allele of the RAGE gene
had significantly lower plasma levels of antioxidants, in-
cluding carotenoids, tocopherol, lutein, and lycopene, than
those with the 1704G allele. These results suggest that
G1704T is involved in oxidative stress. A recent meta-
analysis indicated that the frequency of the 1704 T allele in
East Asian populations was 7.76–20.6%, which is substan-
tially higher than that in Caucasians (4.82–9.92%); more-
over, the ORs associating the 1704 T allele with diabetes
and its complications are higher in East Asian populations
[24]. Moreover, RAGE single-nucleotide polymorphism
rs2060700 (Gly82Ser) is strongly associated with circulating
sRAGE levels [25]. Furthermore, the RAGE Gly82Ser poly-
morphism is associated with a risk of coronary artery dis-
ease [26]. In addition, another RAGE polymorphism might
be linked with insulin resistance [27]. Given these results,
further comprehensive studies including the evaluation of
RAGE polymorphisms are required to clarify the association
between circulating soluble forms of RAGE and MetS.
Recently, the role of circulating sRAGE is conflicting.
Colhoun et al. investigated the relationship of sRAGE to in-
cident coronary heart disease (CHD) in patients with type 2
diabetes [28]. The patients were followed for 3.9 years, and
it was demonstrated that sRAGE concentration were posi-
tively associated with incident CHD in type 2 diabetes [28].
Similar results have been obtained among type 1 diabetes
[29,30] and elderly women [31]. These results suggest that
serum sRAGE concentration has a bivalent role. In condi-
tions of elevated inflammatory level, such as diabetes or
aging, serum sRAGE may be a marker of inflammation
rather than a decoy, because there is emerging evidence
that proteolytic cleavage, through which the component is
formed, is part of a regulatory process and may reflect on-
going inflammation [32]. One would, therefore, expect
higher concentration to be associated with more vascular
disease. In contrast, among our participants, higher sRAGE
concentration was associated with a lower prevalence of
MetS even if they were in the higher hsCRP category. Con-
sistent with our results, Selvin et al. have demonstrated a
negative relationship between low concentration of circulat-
ing sRAGE and the risks of diabetes, CHD, and mortality in
a community-based prospective cohort of middle-aged
adults [33]. Thus, these results suggested that serum
sRAGE concentration may be a marker of inflammation
in conditions of elevated CRP, whereas they may be nega-
tively associated with a risk of cardiovascular diseases and
its risk factors, such as MetS, in conditions of low grade
inflammation.
Momma et al. Diabetology & Metabolic Syndrome 2014, 6:33 Page 9 of 11
http://www.dmsjournal.com/content/6/1/33Although the details of regulation of soluble forms
of RAGE have not been revealed, it is possible that the
risk factors of MetS or cardiovascular diseases might in-
fluence the amount of circulating soluble forms of
RAGE. Previous studies have reported the relationships
between higher serum sRAGE concentration and lower
BMI and WC in general population [5] and non-diabetic
Japanese populations [6], and consistent with this find-
ings, there was a positive correlation with adiponectin
[28]. We also showed that higher sRAGE concentra-
tion was associated with lower prevalence of central
obesity in this study. Thus, although the mechanism of
the association between lower level of circulating sol-
uble forms of RAGE and obesity is not still clear, the
impaired function of adipocyte might be contributing
to lower level of circulating soluble forms of RAGE.
An alternative possibility is an up-regulation of full-
length RAGE shedding by treatment of statin. A recent
in vitro study showed that reduction of cellular choles-
terol by statins significantly increases the levels of
soluble RAGE by enhancement of full-length RAGE
shedding [34]. This result was supported by clinical
studies with hypercholesterolemic [35]. Further experi-
mental studies are necessary to elucidate the regulation
of soluble forms of RAGE.
In addition to central obesity, there was a negative as-
sociation between the prevalence of elevated BP and
serum sRAGE levels. Geroldi et al. showed that the
plasma concentration of sRAGE was lower in hyperten-
sive subjects than in normotensive controls [9]. Because
crosslinking between collagen molecules and AGE could
be implicated in the pathogenesis of arterial stiffening
and hypertension [36], the secreted form of RAGE
could prevent hypertension by binding to circulating
AGE, thus preventing them from forming protein–pro-
tein crosslinks. A significantly elevated AGE concentra-
tion was found in the vascular smooth muscle cells of
spontaneously hypertensive rats [37]. Taken together,
higher circulating sRAGE concentrations may be associ-
ated with lower the prevalence of MetS by lowering the
prevalence of central obesity and elevated BP.
There are some limitations in this study. First, be-
cause the sample size of our female participants was
relatively small, statistical power may not have been
sufficient to obtain statistical significance. Whether the
abovementioned relationship is present in women pop-
ulations remains unknown. Second, because this study
used a cross-sectional design, we cannot conclude the
causal relationship between sRAGE and esRAGE and
the prevalence of MetS and its components. A larger
population-based prospective study needs to be per-
formed to further confirm the causal relationship be-
tween sRAGE and esRAGE and the prevalence of MetS
and its components.Conclusion
In conclusion, higher concentrations of circulating RAGE
were associated with lower prevalence of MetS and its
components including central obesity and elevated BP
among Japanese adult men with low grade inflammation.
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